Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | XIAP | P98170 | 1/20 | 0.55 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MPO | P05164 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12434729 | 1.00 | ALPI (0.55) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL887084 | 1.00 | ALPI (0.55) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL29407854 | 1.00 | ALPI (0.55) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL7018652 | 0.83 | SLC7A5 (0.55) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL4456057 | 0.81 | ALPI (0.49) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL12436130 | 0.80 | MAPT (0.54) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL27135549 | 0.80 | MAPT (0.54) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL7570495 | 0.80 | ALPI (0.47) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL31485501 | 0.79 | KDM4E (0.49) | MEN1KMT2AKDM4EMAPTHTR2A | |
| SCHEMBL31162409 | 0.79 | NOS3 (0.50) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12521455-B2 | Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof | RADIONETICS ONCOLOGY, INC. (US) | 2026-01-13 | — | — | US | claimed |
| US-20250332217-A1 | IMMUNE CHECKPOINT INHIBITOR COMBINATIONS | LYTIX BIOPHARMA AS (NO) | 2025-10-30 | — | — | US | claimed |
| WO-2025217074-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| US-20250312499-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2025-10-09 | — | — | US | claimed |
| EP-4522221-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACID THERAPEUTICS | Entrada Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| US-12239686-B2 | Immune checkpoint inhibitor combinations | LYTIX BIOPHARMA AS (NO) | 2025-03-04 | — | — | US | claimed |
| US-20240293506-A1 | IMMUNE CHECKPOINT INHIBITOR COMBINATIONS | LYTIX BIOPHARMA AS (NO) | 2024-09-05 | — | — | US | claimed |
| CN-117915957-A | Compositions and methods for modulating mRNA splicing | 恩特拉达治疗学股份有限公司 | 2024-04-19 | — | — | CN | claimed |
| EP-4337263-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERFERON REGULATORY FACTOR-5 (IRF-5) ACTIVITY | Entrada Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| EP-4337261-A2 | COMPOSITIONS AND METHODS FOR MODULATING MRNA SPLICING | Entrada Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| US-20130109834-A1 | HIGH SALT-RESISTANCE ANTIBACTERIAL PEPTIDE AND METHOD FOR PRODUCING THE SAME | NATIONAL TSING HUA UNIVERSITY (TW) | 2013-05-02 | — | — | US | claimed |
| EP-2297195-B9 | ANTIBACTERIAL PEPTIDES | SPIDERBIOTECH SRL (IT) | 2012-05-09 | — | — | EP | claimed |
| EP-2402364-A2 | A nonapeptide with anti-tumour activity | Lytix Biopharma AS (NO) | 2012-01-04 | — | — | EP | claimed |
| US-20110318364-A1 | NONAPEPTIDE WITH ANTI-TUMOUR ACTIVITY | LYTIX BIOPHARMA AS (NO) | 2011-12-29 | — | — | US | claimed |
| EP-2297195-B1 | ANTIBACTERIAL PEPTIDES | SPIDERBIOTECH SRL (IT) | 2011-11-16 | — | — | EP | claimed |
| JP-2011521984-A | — | — | 2011-07-28 | — | — | JP | claimed |
| US-20110077192-A1 | Novel Antibacterial Peptides | SPIDERBIOTECH S.R.L. (IT) | 2011-03-31 | — | — | US | claimed |
| EP-2297195-A2 | ANTIBACTERIAL PEPTIDES | Spiderbiotech S.r.l. (IT) | 2011-03-23 | — | — | EP | claimed |
| WO-2009146886-A2 | NOVEL ANTIBACTERIAL PEPTIDES | SPIDERBIOTECH S.R.L. (IT) | 2009-12-10 | — | — | WO | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077192-A1 | Novel Antibacterial Peptides | VIP, NGLY1, NRDC | ALPI 3404/4885PKM 4298/4885PTGS1 4002/4885 |
| US-20250312499-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | KISS1R, GNRHR, PROKR1 | ALPI 3847/4885PKM 1213/4885PTGS1 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.